March 3, 2026Open Access

Metastatic Cutaneous Adnexal Carcinoma of the Head and Neck With Durable Response to an Aromatase Inhibitor Combined With a Cyclin‐Dependent Kinase 4/6 Inhibitor

Key Points

A durable response was observed in a patient with metastatic cutaneous adenocarcinoma after treatment.
Hormonal therapy combined with a cdk4/6 inhibitor proved effective, marking a notable success in this rare cancer.
Routine immunohistochemical assessment of hormone receptors is essential for cutaneous adenocarcinomas in the head and neck region.
The case highlights the potential of targeted therapies in managing challenging cancer cases.

Abstract

This is the first case study describing the success of hormonal therapy combined with a CDK4/6 inhibitor for a rare head and neck cancer. Cutaneous adenocarcinomas in the head and neck region should have routine immunohistochemical assessment of hormone receptors.

Metastatic Cutaneous Adnexal Carcinoma of the Head and Neck With Durable Response to an Aromatase Inhibitor Combined With a Cyclin‐Dependent Kinase 4/6 Inhibitor

Key Points

Abstract

Cite This Study